The role of short-chain fatty acids in microbiota–gut–brain communication
In this article
  1. The role of short-chain fatty acids in microbiota–gut–brain communication
  2. Local effects and metabolism of short-chain fatty acids
  3. The role of SCFAs in gut–brain signalling
  4. Effects on cellular systems
  5. SCFA receptors
  6. Histone deacetylase inhibition
  7. Effects on gut–brain pathways
  8. Immune pathways
  9. Endocrine pathways
  10. Vagus nerve pathways
  11. Other direct humoral pathways
  12. Modulating SCFA production
  13. SCFAs and psychopathological processes
  14. Limitations and future directions
  15. Future directions for studies on the role of SCFAs in the microbiota–gut–brain axis

Author: Dr Károly Krkos, laboratory medicine specialist

“According to our current knowledge, the human body is not an island on its own but part of a super-complex ecological system that carries trillions of bacteria and other microorganisms (the microbiota) on its surfaces (skin, mouth, respiratory system, urogenital organs and, above all, the gut). It has now become clear that the microbiota (mainly the microorganisms living in the gut) influence numerous physiological parameters, including cognitive functions (learning, memory, decision-making processes). The human microbiota is a diverse and dynamic ecological system in a mutualistic relationship with the host.”

(Augusto J. Miontiel-Castro, Rina M. González-Cervates et al.: Frontiers in Integrative Neuroscience, 2013. October, Article 70, doi: 10.3389/fnint.2013.00070)

The role of short-chain fatty acids in microbiota–gut–brain communication

Boushra Dalile, Lukas Van Oudenhove, Bram Vervlietand Kristin Verbeke: Nature Reviews Gastroenterology & Hepatology, 2019 16(8):461-478,

https://doi.org/10.1038/s41575-019-0157-3

Translated into Hungarian by Dr Károly Krkos, 5 January 2020

The gut–brain axis is the two-way connection between the gut and the central nervous system: through complex neurohumoral pathways the brain can alter the sensorimotor and secretory functions of the gut, and conversely, visceral signals arising in the gastrointestinal tract can modulate brain function. The gut microbiota consists of symbiotic and pathological microorganisms, many of which play a fundamental role in gut–brain communication. Disruption of the balance of microbial components is observed in numerous disorders, such as gastrointestinal diseases (e.g. IBS, coeliac disease), metabolic disorders (e.g. obesity and diabetes), and also mental illnesses (eating disorders, ASD, mood disorders and anxiety-related conditions). Microbiota–gut–brain (microbiota-gut-brain, MGB) communication theoretically takes place through a multiplex system that includes the autonomic and enteric nervous systems, the neuroendocrine system and the immune system. The specific mechanisms of this communication and its actual effects on brain development, as well as its cognitive and mood effects, are largely unknown. Short-chain fatty acids (short chain fatty acids, SCFAs) are microbial metabolites derived from the bacterial fermentation of dietary fibre and are prime candidates for mediators involved in this communication.

Local effects and metabolism of short-chain fatty acids

Short-chain fatty acids (SCFAs) are fatty acids with 1–6 carbon atoms (formic acid, acetic acid, propionic acid, butyric acid, valeric acid and caproic acid). Depending on the fibre content of the diet, 500–600 mmol of SCFAs are produced daily, of which the acetate, propionate and butyrate anions predominate in the colon (and in the human body). Their molar ratio is approximately 60:20:20 (acetate: propionate: butyrate), although this ratio depends on the type of substrates available, the composition of the microbiota and the time taken to pass through the gut (transit time) (Table 1). Cow’s milk fat is a non-microbial source of SCFAs: it contains 5–10% butyric acid. SCFAs produced in the colon are rapidly absorbed by active transport mediated by monocarboxylate transporters (MCTs). Another group of transporters is the sodium-dependent monocarboxylate transporters (SMCTs) (the former facilitate SCFA absorption/uptake in an electroneutral way, the latter in an electrogenic way).

SCFAs that enter the cells of the colonic mucosa are metabolised in the citric acid cycle and contribute to ATP production. SCFAs that are not metabolised enter the portal circulation, where the average SCFA concentrations are: acetate – 260 µM, propionate – 30 µM, butyrate – 30 µM. Liver cells also use SCFAs as an energy source. Only a small proportion of the short-chain fatty acids from the colon reaches the circulation (acetate – propionate – butyrate: 36% – 9% – 2%).

Plasma concentrations of the three main SCFAs:

  • acetate: 25.0 – 250.0 µM
  • propionate: 1.4 – 13.4 µM
  • butyrate: 0.5 – 14.2 µM

Table 1: Fibre substrates, their dietary sources and SCFA-producing bacteria

Substrate Dietary source Fermenting bacteria
Resistant starch Cashew nuts, green bananas, white beans, oats and potatoes · Ruminococcus
· Bacteroides
Cellulose Seaweed, cereal bran · Bacteroides
· Ruminococcus
Hemicelluloses (xylan and arabinoxylan) Cereal bran · Bacteroides
· Roseburia
· Prevotella
Pectin Apples, apricots, cherries, oranges, carrots · Eubacterium
· Bacteroides
· Faecalibacterium
Fructans (inulin and fructo-oligosaccharides) Asparagus, leeks, onions, bananas, garlic, chicory, artichokes · Bacteroides
· Faecalibacterium
Milk oligosaccharides Breast milk Bifidobacterium
Lactose (only in lactose intolerance) Milk, yoghurt, buttermilk, cheese Bifidobacterium
β-glucan Oats, barley, wheat, rye, mushrooms, seaweed · Eubacterium
· Atopobium
· Enterococcus
· Lactobacillus
· Prevotella
· Clostridium cluster XIVa
Gum arabic Acacia tree and food additives · Bifidobacterium
· Lactobacillus
· Ruminococcus
Guar gum Guar beans and food additives · Bifidobacterium
· Ruminococcus
Laminarin Seaweed Prevotella
Galacto-oligosaccharides Artichokes, beans, beetroot, broccoli, chickpeas, fennel, lentils, lettuce, red chicory (radicchio), onions Bifidobacterium
Raffinose and stachyose Cottonseed flour, soya flour, onions, chickpeas, beans, peas, lentils · Bifidobacterium
· Lactobacillus

\Based on Joseph J et al.: Front Neurosci 2017, 11: 155 and Basson A et al.: Front Immunol 2016, 7: 290*

SCFAs reach the brain and cross the blood–brain barrier there (based on experimental data). Nevertheless, PET studies with 11C-labelled fatty acids show that SCFA uptake by the brain is minimal.

SCFAs contribute to gut health through numerous local effects:

  • They support the integrity of the intestinal barrier function and inhibit intestinal inflammatory processes. Butyrate enhances intestinal barrier function by regulating the expression of tight junction proteins.
  • SCFAs also influence mucus production in the gut. Acetate and butyrate (but not propionate) increase mucin production after intraluminal administration (in a study of isolated rat intestinal loops).
  • SCFAs also affect gastrointestinal motility (presumably through activation of SCFA receptors: they trigger the release of the gut hormone PYY and cause the release of serotonin from enterochromaffin cells.
  • It has long been known that butyrate inhibits tumour formation and may play a role in reducing the risk of colorectal cancer (it reduces cell proliferation, inhibits the migration of tumour cells, promotes cell differentiation and programmed cell death, inhibits angiogenesis, metastasis formation and tumour cell survival, and also has anti-inflammatory and immunomodulatory effects.

The role of SCFAs in gut–brain signalling

Beyond their local effects on the colon, SCFAs also have intracellular effects:

  • they are endogenous ligands of G protein-coupled receptors (GPCR);
  • by inhibiting histone deacetylases (HDAC), they affect gene expression.

Effects on cellular systems

SCFA receptors

The most studied SCFA receptors are GPR43 and GPR42, later renamed free fatty acid receptors 2 and 3 (FFAR2 and FFAR3). These receptors can be activated by the formate, acetate, propionate and butyrate anions, although with different specificity depending on their carbon chain length. FFAR2 receptors are expressed on enterochromaffin L cells, in blood vessels and on cells of the immune system (lymphocytes, neutrophil granulocytes, monocytes). FFAR3 receptors are expressed in the colon, kidney, sympathetic nervous system and blood vessels. The GPR109A receptor (also known as HCAR2), originally described as a niacin receptor and found in colonic epithelial cells, fat cells and immune cells, can be activated by butyrate and β-D-hydroxybutyrate.

It has been shown that functional SCFA receptors are found in both the central nervous system (CNS) and the peripheral nervous system (PNS). FFAR3, found in the sympathetic ganglia, plays an important role in controlling activation of the sympathetic nervous system.

Both butyrate and propionate increase intestinal gluconeogenesis – the former directly, by activating the gene encoding the catalytic unit of glucose-6-phosphatase (G6PC) and the gene for phosphoenolpyruvate carboxykinase 1 (PCK1); the latter acts indirectly, activating the periportal afferent nervous system via the FFAR3 receptor, which then sends signals to the peripheral and central nervous systems to stimulate intestinal gluconeogenesis.

Histone deacetylase inhibition

Gene expression is regulated by the winding of DNA around histone molecules, mainly through the acetylation of histones. Acetylated histones result in looser, transcriptionally active chromatin. Consequently, the removal of acetyl groups from histones (carried out by histone deacetylase, the HDAC enzyme, results in compact, transcriptionally inactive chromatin. All three SCFAs (acetate, propionate, butyrate) inhibit HDAC, thereby promoting histone hyperacetylation. HDAC plays a role in brain development and in the development of numerous neuropsychiatric diseases (depression, schizophrenia, Alzheimer’s disease, addiction).

In summary, SCFAs may affect brain function through FFAR receptors and/or by inhibiting histone deacetylation. The claims supporting these effects are based on animal data; no human studies have been carried out. It is also uncertain whether different doses of SCFAs may cause global, potentially unfavourable HDAC inhibition or more specific HDAC inhibition that influences psychological responses favourably.

Effects on gut–brain pathways

Immune pathways

Immune responses and inflammation probably play a role in the pathogenesis of psychiatric disorders. CNS–cytokine interactions affect neural processes and influence the functioning of the neural networks that regulate mood, motor activity and motivation. Microglial involvement has been described in numerous psychiatric disorders [depression, schizophrenia, ASD, obsessive-compulsive disorder (OCD)]. The role of SCFAs in intestinal mucosal immunity is well documented. Systemic inflammation can be reduced indirectly by improving gut barrier function. SCFAs act directly on immune cells and immune modulators by maintaining homeostasis.

SCFAs regulate the differentiation, recruitment and activation of neutrophils, dendritic cells, macrophages, monocytes and T cells. Neutrophils are the first to reach the site of inflammation and attract other cells (e.g. macrophages) by releasing cytokines. SCFAs act directly on neutrophil granulocytes by regulating their release of inflammatory cytokines (e.g. TNF) – presumably through HDAC inhibition – and act as neutrophil chemoattractants by regulating the production of chemokines such as CXCL1 and CXCL8. SCFAs induce neutrophil chemotaxis via the FFAR2 receptors found on these cells.

SCFAs inhibit the maturation of monocytes, macrophages and dendritic cells, altering their

Finally, SCFAs can modify adaptive immune responses by modulating T-cell differentiation and proliferation directly and indirectly. Because they inhibit the maturation of dendritic cells (DCs) and their production of immune mediators, they indirectly modify T-cell differentiation. These effects are probably exerted through GPR109A receptors on dendritic cells. Butyrate also induces the expression of two enzymes (indoleamine 2,3-dioxygenase 1 and aldehyde dehydrogenase 1A2) that have immunosuppressive effects and promote the conversion of naive T cells into FOXP3+ regulatory T cells (rather than into pro-inflammatory IFNγ-producing cells).

Systemic inflammation plays an important role in brain immunity and can modify neuroinflammation. According to one study, the microbiota affects the homeostasis, maturation and function of microglial cells in the central nervous system.

All in all, experimental data suggest that the microbiota may affect systemic inflammation and central neuroimmune function, with SCFAs acting as mediators. By acting on various immune cells and influencing inflammatory processes, SCFAs affect the structural and functional integrity of microglia. Treatment with prebiotics appears promising based on mouse experiments, but no human studies have yet been carried out.

Endocrine pathways

SCFAs also affect the gut–brain axis by modifying the secretion of gut hormones. In humans, administration of fermentable polysaccharides raises the levels of PYY and glucagon-like peptide 1 (GLP1). This effect is mediated through activation of GPCR receptors on enteroendocrine L cells. This process in turn acts on the brain networks involved in appetite and food intake, either via the bloodstream or via vagal afferents.

GLP-1 is the best-known incretin hormone, which increases glucose-dependent insulin secretion. This hormone is also produced in the brainstem (nucleus tractus solitarius). GLP1 acts on brain function via humoral and neuronal pathways, and its receptors are found throughout the body (pancreas, gut, heart, lungs, CNS and PNS. Acute administration of GLP1 or a GLP1 agonist is anxiogenic, whereas chronic administration has an antidepressant effect and raises ACTH and cortisol levels. In mice it improves learning and memory, improves neuroplasticity in the hippocampus and is neuroprotective, reducing β-amyloid plaques and microglial activation in an animal model of Alzheimer’s disease.

PYY is another appetite-suppressing neuropeptide that inhibits gastric motility. Besides being produced by the L cells of the ileum and colon, it is also expressed in numerous brain regions, in the highest concentration in the hypothalamus and the pituitary gland. In the circulation it occurs mainly in a truncated form (PYY3-36) and binds primarily to the Y2 neuropeptide Y receptor. Y2 receptor knockout mice cope better with stress and are less prone to anxiety, whereas stimulation of the Y2 receptor triggers anxiety-like and depressive behaviour.

However, it is not clear whether the GLP1 and PYY released from enteroendocrine L cells in response to SCFAs attenuate or trigger stress, anxiety and depressive behaviour.

Other hormones through which SCFAs affect brain function are leptin, ghrelin and insulin, although these hormones have been studied less. Leptin is an anorexigenic hormone produced mainly in fat cells, known mainly for its role in regulating energy balance. It acts through its receptors in the hypothalamus, where orexigenic and anorexigenic neuropeptides (e.g. neuropeptide Y, α-melanocyte-stimulating hormone) are expressed. All three SCFAs appear to affect leptin production, but the direction and mechanism of this effect are not clear. Leptin signalling also affects certain non-hypothalamic regions (cerebral cortex, hippocampus), may modulate numerous brain functions such as reward, motivation and cognition, and affects neuronal plasticity. Disruption of leptin signalling has been observed in Alzheimer’s disease, depression, bipolar disorder and schizophrenia.

Ghrelin is the main orexigenic hormone; it is present mainly in the stomach and duodenum and behaves as a neuropeptide in the central nervous system. It acts on the hypothalamus either via the vagus nerve or by crossing the blood–brain barrier, increasing appetite and prompting the body to take in food. SCFA injection reduced plasma ghrelin concentrations, and the SCFA rise following inulin consumption had a similar effect. The mechanism of this is not clear. Ghrelin also influences many other brain functions, e.g. it modulates stress, depression and anxiety (via the hypothalamic–pituitary–adrenal, HPA, axis), the serotonergic system and the sympathetic nervous system.

The main blood sugar-regulating hormone, insulin, is produced in the pancreas. In humans, feeding with resistant starch, which is fermented into short-chain fatty acids, raised SCFA levels and improved systemic and muscle insulin sensitivity despite reduced insulin levels. Insulin acts as a regulatory peptide in the central nervous system. Peripheral insulin can enter the brain, but the mechanism of this is debated. According to the literature, changes in insulin availability and/or insulin receptor sensitivity are important for brain function, as linked to the mood and cognitive dysfunction of people with Alzheimer’s disease and bipolar disorder (but not depressive disorders). When healthy people were given intranasal insulin, improvements in learning and memory were observed, and the participants also responded better to psychosocial stress.

Vagus nerve pathways

The vagus nerve consists of 80% afferent and 20% efferent fibres. Most afferent fibres terminate in the lamina propria layer of the intestinal mucosa. They are not in direct contact with the microbiota or the gut contents, but they indirectly sense signals coming from the gut lumen, bacterial compounds or metabolites crossing the gut barrier, as well as serotonin and hormones released from enteroendocrine cells. Electrical stimulation of the afferent fibres of the vagus nerve changes neurotransmitter levels in the brain. Certain bacterial strains and their products (LPS) indirectly stimulate the afferent fibres of the vagus nerve and thus affect brain function. For example, chronic treatment of mice with Lactobacillus rhamnosus strain JB1 attenuates stress-induced corticosterone levels and depressive and anxious behaviour, normalises BDNF (brain-derived neurotrophic factor) levels in the hippocampus, and changes GABA mRNA expression in the brain. Similarly, chronic treatment with Bifidobacterium longum strain NCC3001 improves anxiety symptoms triggered by chronic intestinal inflammation. These phenomena can be abolished by vagotomy.

SCFAs can also directly activate the afferent fibres of the vagus nerve. Administration of butyrate, propionate and acetate (separately) intraperitoneally inhibits food intake in mice. The lower ganglion of the vagus nerve (the nodose ganglion) expresses FFAR3 receptors, so SCFAs probably exert their appetite-suppressing effect through these receptors.

Other direct humoral pathways

SCFAs can cross the blood–brain barrier, but their entry appears to be minimal. Animal experiments have shown that both butyrate and propionate improve the integrity of the blood–brain barrier (BBB).

Some animal experiments suggest that SCFAs that enter the central nervous system have neuroactive effects. In mice, transport of acetate across the blood–brain barrier changed the levels of certain neurotransmitters (glutamate, glutamine, GABA) in the hypothalamus and increased the expression of anorexigenic peptides. Propionic acid can induce serotonin synthesis, and propionate and butyrate can increase the biosynthesis of catecholamines (dopamine, noradrenaline, adrenaline).

Dietary fibre and butyrate affect the brain’s neurotrophic factors [nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF)]. These small proteins regulate the growth, survival and differentiation of neurons and synapses in the CNS and PNS, and improve learning and memory (in mice) – as a result of neurotrophic factor mRNA expression due to promoter activation caused by HDAC inhibition.

Serotonin biosynthesis is a further humoral factor in gut–brain communication. More than 90% of the body’s serotonin synthesis takes place in the enterochromaffin cells of the gut, where it regulates several gastrointestinal functions, including motility and secretory reflexes. The remaining proportion of serotonin is produced in the CNS, in the raphe nuclei of the brainstem, and plays a role in mood, appetite, memory, learning and sleep. When SCFAs at physiological concentrations were administered into the proximal colon, this stimulated serotonin release from enterochromaffin cells. Animal experiments suggest that SCFAs play a fundamental role in peripheral serotonin synthesis; on the other hand, they regulate brain function through their effect on the immune system, and play a role in fetal brain development and in signalling to the brain via serotonin receptors on the afferent fibres of the vagus nerve.

In summary, SCFAs can affect the brain directly, since they can cross the BBB, strengthen BBB integrity, modulate neurotransmission, affect the levels of neurotrophic factors and promote serotonin biosynthesis. These findings are based mainly on animal experiments. Whether SCFAs produced by the microbiota at physiologically relevant concentrations have a similar effect in the human CNS requires further analysis.

Modulating SCFA production

SCFA production can be influenced indirectly by manipulating the gut microbiota, by giving live beneficial bacteria (probiotics). An alternative is to incorporate prebiotics into the diet. Prebiotics are bacterial substrates in the colon from which the microbiota ferments SCFAs. Numerous data confirm that giving probiotics or prebiotics, or introducing a plant-dominated Mediterranean diet, increases SCFA production in the colon. Nevertheless, there are few studies that have examined the physiological effect of known amounts of SCFAs.

In a mouse line with vascular dementia, administration of Clostridium butyricum increased faecal and brain SCFA levels, which significantly reduced the symptoms of cognitive impairment and the histopathological changes in the hippocampus. In mice fed fructo-oligosaccharides and galacto-oligosaccharides (prebiotics) for 3 weeks, stress-induced corticosterone release decreased, pro-inflammatory cytokine levels were reduced, gene expression in the hippocampus and hypothalamus was modified, and acetate and propionate levels in the caecum rose. Caecal SCFA levels correlated with reduced depressive and anxiety symptoms.

Further studies are needed to evaluate the role of SCFAs in the behavioural changes achieved by giving probiotics and prebiotics.

SCFAs and psychopathological processes

Although numerous experimental data support the role of SCFAs in MGB communication, only a few heterogeneous and contradictory studies have been published on their direct role in one or more areas of psychological functioning. Nevertheless, SCFAs have so far been used in several neuropsychiatric diseases.

People with Parkinson’s disease have fewer SCFA-producing bacteria than healthy people and a lower faecal SCFA content compared with age-matched control groups. In animal models of Parkinson’s disease, butyrate administration was found to improve motor function and lessen dopamine deficiency. However, in a mouse model of Parkinson’s disease in which overproduction of the protein α-synuclein could be shown, an orally administered SCFA mixture increased neuroinflammation and motor deficits compared with germ-free or antibiotic-treated mice. This suggests that, with a certain genetic predisposition, SCFA administration may be accompanied by a flare-up of Parkinson’s disease symptoms.

The main pathological processes characteristic of Alzheimer’s disease can be modified by SCFA administration. In a mouse model of the disease, SCFA administration was associated with improved memory and with expression of associative learning genes via HDAC inhibition. In another study, valeric acid, butyric acid and propionic acid inhibited the interaction of β-amyloid peptides and thus prevented the formation of neurotoxic oligomers.

In autism spectrum disorders (ASD), the role of SCFAs is contradictory. In studies of children with ASD, one study found a lower (Adams J B et al.: BMC Gastroenterol 2011, 11:22) and another (Wang L et al.: Digest Dis Sci 2012, 57:2096) a higher faecal SCFA content than in healthy children. Altered SCFA levels may be linked to the fibre content of the food eaten, changes in the composition of the gut microbiota and variability in gut transit time. In a mouse model of ASD, treatment with butyrate reduced social behaviour deficits by modifying GABA signalling and the transcription of certain genes in the frontal cortex. Finally, giving SCFAs (mainly propionate) to rodents in various ways (into the cerebral ventricles, intraperitoneally, subcutaneously, orally) induced behavioural and brain changes characteristic of patients with ASD. As the results in ASD are contradictory, further studies are needed. One problem is finding a suitable animal model that matches the characteristics of most patients with ASD in both behaviour and metabolic profile.

According to two studies, faecal SCFA concentrations are lower in patients with depression than in healthy people. When faecal microbiota transplantation (FMT) was performed on microbiota-depleted rats using samples from patients with depression, the experimental animals developed anxiety symptoms.

In an animal model of mania, administration of sodium butyrate abolished hyperactivity, restored the function of the mitochondrial respiratory chain in the prefrontal cortex, hippocampus, striatum and amygdala, and reversed mania-like and depression-like symptoms.

The indirect effects of SCFAs have also been studied in various neuropsychiatric conditions. For example, when patients with schizophrenia were put on an SCFA-rich Mediterranean diet, their mortality related to the immune and cardiovascular problems characteristic of this disease group decreased.

The beneficial effects of SCFAs (improved metabolic adaptation, reduced neuroinflammation, impaired spatial memory, abnormal systolic blood pressure, restoration of functional connectivity) have been demonstrated by imaging studies (e.g. functional MRI).

Limitations and future directions

Studies to date suggest that SCFAs also play a role in neurological and neuropsychiatric conditions and in psychological processes. On the basis of the data so far, however, it cannot yet be decided whether this effect is favourable or unfavourable. A main common feature of both observational and experimental studies is that they take faecal SCFA content into account. This figure, however, gives information about the short-chain fatty acids that were not absorbed and does not inform about the rate of in situ SCFA production, the extent of their absorption or their interaction with relevant molecules and cell types. This lack of knowledge hinders our understanding of the psychological and biological effects of SCFAs. Understanding these processes requires knowing what proportion of the SCFAs produced reaches the systemic circulation. According to the results of a stable isotope study carried out in 2017, 36% of 13C-labelled acetate, 9% of propionate and 2% of butyrate delivered to the colon by a special capsule reached the bloodstream.

Moreover, quantitative measurement of the SCFAs that reach the bloodstream does not explain the differences between the findings of animal experiments and observations in humans. The main problem with animal models is how far the animal microbiota and gastrointestinal system correspond to those of humans, and how well the animal model reproduces the phenotype of the human disease being studied. For example, the proportions of the main bacterial phyla differ between humans and rodents. In mice the caecum is proportionally much larger than in humans. The anatomical and microbiota differences mean different fibre fermentation. The gastrointestinal system and gut microbiota composition of piglets and chimpanzees are more similar to those of humans, but for practical and ethical reasons the use of these animals to study the MGB axis is limited.

Reliable animal modelling of neuropsychiatric diseases is rather questionable. To begin with, even the latest DSM (Diagnostic and Statistical Manual) of mental disorders does not draw sharp boundaries between different diseases or between pathological and healthy states; moreover, certain symptoms (e.g. sadness, guilt) cannot be assessed in animal models. Nor should we forget that animal models are mostly created by mutating a single gene, one that in humans may be associated with several psychiatric diseases (e.g. a mutation of the DISC1 gene may be associated with depression, bipolar disorder and schizophrenia within the same family). In addition, there is no model that reproduces all the aetiological factors, developmental processes and temporal dynamics of human diseases.

Current requirements for models of psychiatric disorders are that they should be endophenotype-based and symptom-based, representing “a discrete pathological process characterising a biological system rather than a nosological entity”.

In summary, future research should study models that adequately reflect the human microbiome and focus on a single endophenotype of a psychiatric disease.

Future directions for studies on the role of SCFAs in the microbiota–gut–brain axis

  • In interventions with probiotics, prebiotics and dietary fibre, the levels of short-chain fatty acids in the systemic circulation must be measured.
  • Mediation analysis should be used to determine the extent to which the SCFA intervention contributes to the psychological effect under study.
  • The effect of SCFA administration on psychological functions also needs to be studied directly in humans.
  • The effect of the amount of SCFAs measured in the systemic circulation on psychopathological processes should be evaluated in comparison with faecal SCFA content.
  • It should be studied whether changes in SCFA production cause changes in other factors involved in microbiota–gut–brain interactions (the immune and endocrine systems).

Book a food intolerance test

Food intolerance

Don't just get the school bag ready

Starting school is not only about new exercise books and a changed daily routine but also about reorganising family meals. The FOODTEST Children's pac...

Food intolerance

IBS and food intolerance: can diet help?

Several factors may lie behind irritable bowel syndrome, and the role of diet may also come up. The article explains in plain terms how certain foods...

Related articles